Cagrilintide is a long-acting synthetic analog of the hormone amylin, engineered with residue substitutions, an intramolecular disulfide bridge, and a fatty-acid (acyl) modification that together extend its stability well beyond that of the native peptide. Each structural feature addresses a specific limitation of amylin as a research molecule.
The amylin scaffold
Native amylin is a small peptide hormone co-secreted with insulin, but it is prone to aggregation and has a short in-vitro lifetime. Cagrilintide preserves the recognizable amylin architecture while modifying the parts of the sequence responsible for instability, as introduced in the cagrilintide research overview.
Disulfide ring
An internal disulfide bond links two cysteine residues to form a small ring near one end of the chain — a hallmark of the amylin/calcitonin peptide family. This ring helps fix the conformation the peptide needs to engage its receptor system, a feature behind its mechanism of action.
Acylation for longevity
A lipid (fatty-acid) side chain is attached to promote reversible binding to serum albumin, which slows clearance and produces a long-acting profile in model systems. This acylation strategy is a common theme in modern metabolic-peptide engineering.
Aggregation-resistant substitutions
Substitutions relative to native amylin improve solubility and resistance to the aggregation that limits the parent hormone; the general logic of sequence-driven properties is covered in understanding amino acid sequences.
Synthesis and QC
Assembly by solid-phase synthesis with controlled disulfide formation, followed by lyophilization (what is lyophilization) and HPLC verification, completes the material. Identity of the correct disulfide-cyclized product is a key quality checkpoint.
Managing a modified peptide during assembly
Long, acylated, disulfide-containing peptides present several manufacturing challenges at once. Side-chain protecting groups must survive chain elongation yet be removable without damaging the product, the lipid attachment must occur at the intended site, and oxidation must yield the correct intramolecular bridge rather than intermolecular species. Purification separates deletion sequences, acylation variants, and mispaired or aggregated material.
What a quality record should establish
A useful analytical package distinguishes identity from purity. Expected mass supports sequence and modification identity; chromatographic data estimate the relative abundance of the main component; and additional characterization may support correct disulfide formation. Because acylation and oxidation both change mass and retention behavior, records should describe the intended molecular form rather than reporting only a generic peptide name.
Product page: Cagrilintide research vials.
Research Use Only. Supplied strictly for laboratory research and development — not for human or veterinary use, consumption, or any therapeutic or diagnostic purpose. This article is research education, not usage guidance.